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Abstract
Introduction: High failure rates of new investigational drugs have impaired the development of breast cancer
therapies. One challenge is that excellent activity in preclinical models, such as established cancer cell lines, does
not always translate into improved clinical outcomes for patients. New preclinical models, which better replicate
clinically-relevant attributes of cancer, such as chemoresistance, metastasis and cellular heterogeneity, may identify
novel anti-cancer mechanisms and increase the success of drug development.
Methods: Metastatic breast cancer cells were obtained from pleural effusions of consented patients whose disease
had progressed. Normal primary human breast cells were collected from a reduction mammoplasty and
immortalized with human telomerase. The patient-derived cells were characterized to determine their cellular
heterogeneity and proliferation rate by flow cytometry, while dose response curves were performed for
chemotherapies to assess resistance. A screen was developed to measure the differential activity of small molecules
on the growth and survival of patient-derived normal breast and metastatic, chemoresistant tumor cells to identify
selective anti-cancer compounds. Several hits were identified and validated in dose response assays. One
compound, C-6, was further characterized for its effect on cell cycle and cell death in cancer cells.
Results: Patient-derived cells were found to be more heterogeneous, with reduced proliferation rates and
enhanced resistance to chemotherapy compared to established cell lines. A screen was subsequently developed
that utilized both tumor and normal patient-derived cells. Several compounds were identified, which selectively
targeted tumor cells, but not normal cells. Compound C-6 was found to inhibit proliferation and induce cell death
in tumor cells via a caspase-independent mechanism.
Conclusions: Short-term culture of patient-derived cells retained more clinically relevant features of breast cancer
compared to established cell lines. The low proliferation rate and chemoresistance make patient-derived cells an
excellent tool in preclinical drug development.
Introduction
Over the last 40 years, advances in the development of
breast cancer drugs have led to improved treatments
and outcomes for patients [1,2]. However, mortality,
which is generally attributed to metastatic disease and
resistance to chemotherapy, has remained relatively
unchanged over the same period [3,4]. In addition,
many cancer drugs have significant toxicity, which
impacts a patient’s compliance with treatment and can
result in serious long-term health effects [5]. These
issues highlight the urgent need to develop new drugs
that can target the chemoresistant disease while simulta-
neously reducing general toxicity to the patient.
Bringing a new investigational drug to the clinic is
challenging and plagued by high failure rates [6,7].
Often, excellent efficacy in preclinical models does not
translate into improved survival. One factor that may
contribute to the high failure rate is a reliance on
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human preclinical models that do not accurately repli-
cate clinical outcomes. For example, the most widely
used in vitro model of breast cancer is established cell
lines [8-10]. Even though cell lines share many molecu-
lar and genomic characteristics of breast cancer, their
adaptation to culture can impart significant undesirable
attributes that affect preclinical studies [11-13]. Com-
pared to patient tumors, cell lines often exhibit
increased proliferation, altered sensitivity to chemother-
apy and reduced cellular heterogeneity [14-16]. Incor-
poration of new models that more accurately replicate
features of cancer observed in patients, such as che-
moresistance, metastasis and cellular heterogeneity, into
drug development programs may lead to more success-
ful clinical results for investigational therapeutics.
An alternative to established cell lines is the use of
patient-derived tissue that is only briefly maintained in
culture [8,14,17]. Short-term culture of patient-derived
tissue is believed to retain many key features of the ori-
ginal tumor, including heterogeneity, proliferation rate
and gene expression profiles [18]. In addition, tissue
derived from patients previously treated with che-
motherapy can acquire resistance through mechanisms
developed naturally during the clinical course of therapy
[19]. Therefore, incorporation of short-term cultures of
patient-derived cells in drug screening assays is likely to
identify compounds that circumvent chemoresistant
pathways. Herein, we report the development of a drug
screen to identify small molecules capable of selectively
targeting chemoresistant patient-derived cancer cells.
Methods
Tissue culture and reagents
MCF-7 and MCF-10A cells were cultured with (D)
MEM/F12 media with 2.5 mM L-glutamine and 15 mM
HEPES buffer (HyClone, Logan, UT, USA) and the
MDA-MB-231 and T47D cells were cultured with
RPMI-1640 medium with 2.5 mM L-glutamine and 25
mM HEPES buffer (HyClone) at 37°C with 5% CO2.
Both media were supplemented with 10% fetal bovine
serum (heat inactivated, HyClone), 5.0 μg/mL of insulin-
transferrin-selenium-X (ITS-X) (Life Technologies,
Grand Island, NY, USA), penicillin-streptomycin-gluta-
mine (Life Technologies), and 2.5 nM epidermal growth
factor (EGF), recombinant human (BD Biosciences, San
Jose, CA, USA).
De-identified pleural effusion (PE) and reduction
mammoplasty tissue were collected by the Huntsman
Cancer Institute Tissue Resource and Applications Core
Facility with informed consent from patients at the
Huntsman Cancer Hospital and the University of Utah
Hospitals and Clinics under a protocol approved by the
University of Utah Institutional Review Board [20]. Cells
from freshly acquired effusion fluid were collected by
centrifugation, washed with PBS and cryopreserved in
10% dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO,
USA) and 90% human breast epithelial medium, which
consists of (D)MEM/F12 supplemented with 15 mM
HEPES, 5% fetal bovine serum (FBS), 1 mg/mL BSA
(Sigma), 1 μg/mL ITS-X, 0.5 μg/mL hydrocortisone
(Sigma), and 50 μg/mL gentamycin (Hyclone).
Tissue collected from a consented patient undergoing
a voluntary reduction mammoplasty was digested with 2
mg/mL of collagenase (Sigma) and 100 U/mL of hyalur-
onidase (Sigma) at 37°C overnight to generate organoids.
The organoids were cultured in modified M87 media,
which consists of (D)MEM/F12 supplemented with 15
mM HEPES, 2% FBS, ITS-X, penicillin-streptomycin-
glutamine, 5 ng/mL EGF, 0.3 μg/mL hydrocortisone, 0.5
ng/mL cholera toxin (Sigma), 5 nM 3,3’,5-triiodo-L-thyr-
onine (Sigma), 0.5 nM b-estradiol (Sigma), 5 μM
(±)-isoproterenol hydrochloride (Sigma), 50 nM ethano-
lamine (Sigma) and 50 nM O-phosphorylethanolamine
(Sigma) [21]. After two passages, the cells were immor-
talized utilizing a concentrated lentivirus that expresses
the human telomerase gene under the control of the
EF1a promoter at a multiplicity of infection (MOI) of
20. The immortalized cells, hTERT-HMEC, were subse-
quently expanded and early passages were cryopreserved
in 10% DMSO and 90% modified M87 media. Both the
hTERT-HMEC and patient-derived pleural effusion
were cultured in modified M87 media at 37°C with 5%
CO2. For each experiment requiring PE cells, only non-
passaged, freshly defrosted cells were used following an
18-hour culture in modified M87 media. All hTERT-
HMEC cells used were less than eight passages post
immortalization, and primary PE cells were not cultured
for longer than one week for any assay.
The following compounds were dissolved in DMSO
(Sigma) and stored at -20°C: doxorubicin hydrochloride
(Tocris Bioscience, Minneapolis, MN, USA), paclitaxel
(taxol) (EMD Millipore, Billerica, MA, USA), gemcita-
bine hydrochloride (Sigma), 17-(allylamino)-17-
demethoxygeldanamycin (17-AAG) (LC Laboratories,
Woburn, MA, USA), bortezomib (LC Laboratories),
panobinostat (LBH589) (Selleckchem, Houston, TX,
USA), cis-diammineplatinum (II) dichloride (cisplatin)
(Sigma), and staurosporine (Sigma). Chloroquine
(Sigma) and tumor necrosis factor-related apoptosis
inducing ligand (TRAIL), recombinant human (EMD
Millipore) were dissolved in sterile water and were
stored at -20°C. The small molecule C-6 was synthesized
according to a previously published method [22], was
dissolved in DMSO and stored at -20°C. For all experi-
ments, the cells were seeded in their respective media
and were allowed to recover overnight. Compounds
were subsequently diluted in the corresponding media
containing 2% FBS as well as a matched vehicle control,
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which did not exceed a final DMSO concentration of
0.2% (v/v).
Cell characterization by flow cytometry
Non-confluent cultures of cell lines were trypsinized
into single cell suspensions, washed with Hank’s
balanced salt solution (HBSS) supplemented with 2%
FBS and counted. About 1.0 × 106 cells were incubated
with fluorescently-conjugated antibodies for human
CD24-fluorescein isothiocyanate (FITC) and CD44-allo-
phycocyanin (APC) (BD Biosciences) on ice for 30 min-
utes. An additional 1.0 × 106 cells were stained with
antibodies for human CD49f-FITC and EPCAM-APC
(BD Biosciences) on ice for 30 minutes. Cell suspensions
were subsequently washed with HBSS containing 2%
FBS, resuspended at 3.0 × 106 cells/mL and were stained
with 7-amino-actinomycin D (7-AAD) (BD Biosciences)
on ice for 15 minutes. Cell suspensions were passed
through a 70-μm cell strainer and were analyzed using a
FACScan flow cytometer (BD Biosciences). The result-
ing data were analyzed with Flow Jo software (Tree Star,
Ashland, OR, USA).
Patient-derived pleural effusion cells and hTERT-
HMEC cells were cultured for two days in modified
M87 media. Cells in suspension were collected and
adherent cells were trypsinized and combined with the
suspension cells. The resulting single cells were washed
with HBSS containing 2% FBS and were counted. Two
vials containing 1.0 × 106 cells were stained with a cock-
tail of phycoerythrin conjugated antibodies for human
CD2, CD3, CD10, CD16, CD18, CD31, CD64 and
CD140b (BD Biosciences) to exclude lineage positive
cells (non-epithelial). Simultaneously, one vial was also
stained with antibodies for human CD24-FITC and
CD44-APC on ice for 30 minutes. The additional vial
was stained with antibodies for human CD49f-FITC and
EPCAM-APC (BD Biosciences) on ice for 30 minutes.
Cell suspensions were subsequently washed with HBSS
containing 2% FBS, resuspended at 3.0 × 106 cells/mL
and were stained with 7-AAD on ice for 15 minutes.
Cell suspensions were passed through a 70-μm cell
strainer and were analyzed using a FACScan flow cyt-
ometer. The resulting data were analyzed with Flow Jo
software.
Dose response assays
Cells were seeded in white 96-well plates (Costar,
Tewksbury, MA, USA) in 100 μL of their respective
media at varying densities to achieve 80% to 90% con-
fluency after five days in culture. The compounds dis-
solved in DMSO were diluted in their corresponding
media containing 2% FBS and an EP Motion 5075
(Eppendorf North America, Hauppauge, NY, USA)
liquid handler was utilized to perform a serial dilution.
In addition, a vehicle control corresponding to the high-
est DMSO concentration, which did not exceed 0.2%
(v/v), was also prepared. After the cells were cultured for
24 hours, the media were aspirated and the cells were
treated with the compounds and vehicle controls in tri-
plicate. After four days of treatment, viability was deter-
mined utilizing the ATPlite 1step assay system (Perkin
Elmer, Waltham, MA, USA) according to the manufac-
turer’s instructions. Luminescence measurements were
acquired utilizing a Perkin Elmer 2104 EnVision plate
reader. Raw luminescence values were normalized to the
DMSO vehicle control wells. Normalized values were
plotted as an average ± SD of three wells per concentra-
tion and these data were analyzed using the dose
response nonlinear curve fitting function with Prism 5.0
(GraphPad Software, La Jolla, CA, USA) to determine the
half maximal effective concentration (EC50).
BrdU proliferation and cell cycle analysis
Cells were seeded in six-well plates (BD Falcon) in their
respective media at different densities to attain 70% to
80% confluency at the end of the assay. In order to
compare the proliferation rate of established cell lines
compared to patient-derived cells, 10 μM of 5-bromo-2-
deoxyuridine (BrdU) (Sigma) was added to the culture
media for 30 minutes or 6 hours in triplicate. To deter-
mine the impact of C-6 on the cell cycle, cells were
treated with 15 μM C-6 or 0.02% (v/v) DMSO vehicle in
the corresponding media containing 2% FBS for 24 and
48 hours in triplicate followed by treatment with 10 μM
BrdU for 30 minutes. Immediately following BrdU treat-
ment, floating cells were collected and adherent cells
were trypsinized. Floating and adherent cells were com-
bined, washed with HBSS containing 2% FBS, fixed with
70% ethanol and stored overnight at -20°C. Cells were
then treated with 2 M HCl containing 0.5% Triton X-
100 (EMD Millipore) for 30 minutes at room tempera-
ture and were washed with 0.1 M sodium tetraborate
(Sigma) at pH = 8.5. Next, cells were blocked with stain-
ing buffer, which consisted of 1% BSA, 0.5% Tween-20
(Fisher Scientific) in PBS, for five minutes and were
stained with a mouse monoclonal BrdU antibody
(Developmental Studies Hybridoma Bank, Iowa City, IA,
USA) for one hour on ice. Cells were subsequently
washed and stained with anti-mouse Alexa Fluor® 488
(Life Technologies) for 30 minutes on ice, washed,
stained with 5 μg/mL of propidium iodide (EMD Milli-
pore) and passed through a 70-μm cell strainer. Cell
suspensions were analyzed using a FACScan flow cyt-
ometer and the resulting data were analyzed with Flow
Jo software. The average ± SD of three wells for each
condition was calculated.
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Measurement of proliferation by EdU incorporation
Cells were seeded in six-well plates and allowed to
recover for 18 hours. Following the recovery time, 10
μM of 5-ethynyl-2’-deoxyuridine (EdU) (Molecular
Probes) was added to the culture media of triplicate
samples and the cells were cultured for 30 minutes or
six hours. EdU incorporation was then quantified by
flow cytometry using the Click-iT EdU Alexa Fluor 647
flow cytometry assay kit (Molecular Probes). The aver-
age ± SD of three wells for each condition was
calculated.
Characterization of mammary epithelial cell lineage
markers
Non-passaged patient-derived plural effusion cells were
defrosted and washed two times with HBSS. Cells were
either stained immediately for mammary epithelial cell
lineage markers or cultured for 96 hours and then
stained. For staining, cytospin slides were prepared
using 125,000 cells per slide (900 RPM, 10 minutes,
Thermo Scientific Cytospin 4). The cells were fixed in
4% paraformaldehyde, permeabilized with 0.2% Triton
X-100, and blocked with 1% BSA in PBS. The cells were
then stained with antibodies for cytokeratin-8 (Develop-
mental Studies Hybridoma Bank) and cytokeratin-14
(Covance). Following incubation with the appropriate
secondary antibody (Alexa Fluor-conjugated IgG, Life
Technologies) and 4’,6-diamidino-2-phenylindole
(DAPI), the slides were imaged using an IX81 micro-
scope (Olympus, Center Valley, PA, USA).
In vivo assessment of tumorigenicity
Three-week old female non-obese/severe combined
immunodeficiency (NOD/SCID) mice were obtained
from Jackson Labs (Bar Harbor, ME, USA) and main-
tained in a pathogen-free animal facility. All procedures
were carried out in accordance with University of Utah-
approved Institutional Animal Care and Use Committee
protocols. The method used to assess the transformation
capacity of primary reduction mammoplasty cells was
performed similarly to those previously described [23].
Human mammary epithelial cells (HMEC) cells were
infected individually or in combination with lentiviruses
containing the human telomerase reverse transcriptase
(hTERT) gene, the large T antigen of simian virus 40
(SV40-LT) gene and a constitutively active form of the
human Ras (RasV12) gene. All genes were driven by the
ubiquitously expressed EF1-a promoter. Cells were cul-
tured in a supplemented media (modified M87) either
in monolayer or in suspension. The day of the trans-
plant, cells were washed and resuspended in Matrigel.
The number 4 inguinal fat pad was cleared on one side
and each recipient mouse received a 10 μL injection of
approximately 750,000 cells suspended in Matrigel. At a
minimum of forty-eight days post surgery, the trans-
planted glands were resected and fixed in 4% parafor-
maldehyde. The fixed tissue was then stained with
carmine alum (Sigma) for 24 hours. Following one wash
each in 70%, 95% and 100% ethanol, the gland was
examined for the presence of tumors.
Chemical screen
The hTERT-HMEC and PE1007070 cells were seeded in
white 96-well plates (Costar) in 100 μL of modified M87
media at varying densities to achieve 80% to 90% con-
fluency at the end of the assay. The 10 mM DMSO
stock solutions from the 560-compound University of
Utah Department of Chemistry library were diluted with
modified M87 media utilizing an EP Motion 5075
(Eppendorf North America) liquid handler. In addition,
corresponding DMSO vehicle and doxorubicin controls
were prepared in modified M87 media. After the cells
were cultured for 24 hours, 80 μL of media was aspi-
rated from each well. Immediately, either 130 μL of the
diluted compounds, DMSO vehicle or doxorubicin con-
trols were added to each well in duplicate to achieve a
final concentration of 20 μM for each compound with a
DMSO concentration of 0.2% (v/v). After four days of
treatment, viability was determined utilizing the ATPlite
1step assay system (Perkin Elmer) according to the man-
ufacturer’s instructions. Luminescence measurements
were acquired utilizing a Perkin Elmer 2104 EnVision
plate reader. Raw luminescence values were normalized
to the DMSO vehicle control wells for each plate and
cell type. Normalized average values for the PE1007070
cells were subtracted from the hTERT-HMEC cells to
determine the selectivity for each compound. In addi-
tion, the normalized 20 μM doxorubicin and DMSO
values were used to calculate the Z’-factor for each plate
[24]. Additional information about the screen can be
found in Additional file 1, Table S1.
Live/dead assay
The hTERT-HMEC and PE1007070 cells were seeded in
black wall clear bottom 96-well plates (Greiner Bio-one,
Monroe, NC, USA) in 100 μL of modified M87 media at
varying densities to achieve 80% to 90% confluency at
the end of the assay. After 24 hours, the media were
aspirated and the cells were treated with 20 μM C-6 or
the corresponding 0.02% (v/v) DMSO vehicle control.
After culturing for five days, the viability and cytotoxi-
city was determined with the Live/dead assay (Life
Technologies) according to the manufacturer’s instruc-
tions. Briefly, the media were aspirated and the cells
were treated with 4 μM Calcein-AM and 8 μM Ethi-
dium homodimer-1 diluted in (D)MEM/F12 for 30 min-
utes at 37°C. Subsequent imaging was performed with
an IX81 microscope (Olympus, Center Valley, PA, USA)
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running Slide Book 5.0 software (Intelligent Imaging
Innovations, Denver, CO, USA).
For the three dimensional culture experiments,
PE904557a, PE900642a and PE11000025 cells were
seeded in a 24-well ultra low adhesion plate (Costar) at
approximately 2 × 106 cells/mL in mammary epithelial
cell growth medium (MEGM) complete media (Lonza,
Basel Switzerland) and were cultured overnight. The
resulting aggregates were separated from single cells by
differential centrifugation. Next, 20 μL of growth factor
reduced Matrigel (BD Biosciences) was added to each
well of a black walled clear bottom 24-well plate (Grei-
ner Bio-one) and was allowed to solidify to form a base
layer. The aggregates were then suspended in Matrigel
on ice and approximately 300 aggregates in 40 μL were
added to each well. After the Matrigel solidified, modi-
fied M87 media was added to each well and the cells
were cultured overnight. The media were subsequently
aspirated and the cells were treated with 30 or 60 μM
C-6 or the corresponding 0.06% (v/v) DMSO vehicle
control. After culturing for five days, the viability and
cytotoxicity were determined utilizing the Live/dead
assay (Life Technologies) in the same manner as
described above. Multiple Z-planes of the organoids
were subsequently imaged utilizing an IX81 microscope
(Olympus) running Slide Book 5.0 software (Intelligent
Imaging Innovations).
AAF-Glo and caspase-Glo assays
Adherent cells were seeded in two identical white 96-
well plates (Costar) in 100 μL of their respective media
at varying densities to achieve 80% to 90% confluency at
the end of the assay. After 24 hours, the media were
aspirated and the cells were treated with 30 μM C-6 or
a matched 0.03% (v/v) DMSO vehicle control in the cor-
responding media containing 2% FBS. For suspension
cultures, cells were first seeded in 75 μL of media. At
the start of treatment, 25 μL of a 4× concentration of
C-6 or a matched (v/v) DMSO vehicle control was
added to each well such that the final volume in each
well was 100 μL and the final concentration of C-6 was
30 μM. For the caspase activity assays, additional wells
were treated with 1 μM staurosporine. After culturing
for the appropriate amount of time, either the AAF-Glo
or Caspase-Glo assays (Promega, Madison, WI, USA)
were performed on one 96-well plate according to the
manufacturer’s instructions. For the Caspase-Glo assay,
cell viability was determined for the additional 96-well
plate utilizing the ATPlite 1step assay system (Perkin
Elmer) according to the manufacturer’s instructions. For
the AAF-Glo assay, the total protein in each well of the
additional plate was measured using the BCA protein
assay kit (Peirce, Rockford, IL, USA). Luminescence
measurements were acquired utilizing a Perkin Elmer
2104 EnVision plate reader. Raw luminescence values
for each assay were normalized to the DMSO vehicle
control wells. The values for the Caspase-Glo or AAF-
Glo assays were then normalized to the ATPlite values
or total protein, respectively, in order to account for dif-
ferences in cell numbers and were plotted as an average
± SD of four wells per condition.
Western blot analysis
Cells were lysed in cold radioimmunoprecipitation assay
buffer (50 mM Tris HCl, 150 mM NaCl, 0.1% sodium
dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 1%
Triton X-100, pH = 8.0) supplemented with protease
inhibitor cocktail (Sigma), phosphatase inhibitor cocktail
2 (Sigma) and 1 mM dithiothreitol (DTT) (Sigma). The
lysate was sonicated for 30 seconds using a 450 Sonifier
(Branson Ultrasonics, Danbury, CT, USA) and was cen-
trifuged at 14,000 RPM for five minutes at 4°C. The
protein concentration was determined using the BCA
protein assay kit (Peirce, Rockford, IL, USA) and the
samples were boiled for five minutes with 4× SDS
Laemmli buffer. Equal amounts of protein were resolved
on SDS polyacrylamide gels and transferred to an
Immobilon-FL PVDF membrane (EMD Millipore). Blots
were blocked in Odyssey Blocking Buffer (LI-COR, Lin-
coln, NE, USA) for one hour at room temperature,
stained with primary antibodies overnight at 4°C,
washed, and stained with IR800CW or IR680 anti-
mouse or rabbit secondary antibodies (LI-COR) for one
hour at room temperature. Blots were imaged with the
Odyssey Infrared Imaging System (LI-COR). The follow-
ing primary antibodies were purchased from Cell Signal-
ing (Danvers, MA, USA): caspase-8, cleaved caspase-9,
PARP and LC3A/B. In addition, active caspase-3 anti-
body was purchased from BD Biosciences and both vin-
culin and a-tubulin antibodies were obtained from
Sigma.
Statistics
An unpaired students t-test using Welch’s correction
was performed using Graph Pad Prism 5.0 and P < 0.05
between groups was considered significant.
Results
Patient-derived cells replicate the cellular heterogeneity,
proliferation rate and chemo-sensitivity of normal and
cancer tissue
We sought to utilize a novel therapeutic screen to iden-
tify compounds that selectively target patient-derived
chemoresistant breast cancer cells while exhibiting lim-
ited toxicity to normal human breast tissue. For the
screen, tumor cells were isolated from patients who pre-
sented with a pleural effusion (PE), which is a buildup
of fluid and metastatic breast cancer cells in their
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pleural cavity. We obtained 1.0 × 109 cells from a
patient (PE1007070) who was initially diagnosed with an
ER- PR- HER2- primary tumor, and 2.0 × 108 viable
cells from a patient (PE1008032) who had an ER+ PR+
HER2+ tumor. The PEs were collected after both
patients relapsed following numerous rounds of che-
motherapy (additional information can be found in
Additional file 2, Table S2). In addition, we generated a
non-transformed primary mammary epithelial control
cell line to determine the general toxicity of each com-
pound. Viable primary HMECs were isolated from a 25-
year-old patient undergoing a reduction mammoplasty
who had no known family history of breast cancer. The
HMECs were immortalized with a lentivirus expressing
the human telomerase gene (hTERT) under the control
of the ubiquitous EF1a promoter to generate a low pas-
sage human hTERT-HMEC control cell line [21], which
did not form tumors when transplanted orthotopically
into NOD/SCID mice [see Additional file 3, Table S3].
We next characterized the cellular heterogeneity of PE
cells by both immunofluorescence and fluorescence acti-
vated cell sorting (FACS) of cell surface proteins. Immu-
nofluorescence of PE tumor cells derived either directly
from the patient or after culturing for 96 hours demon-
strated the presence of both luminal (keratin-8 positive)
and basal (keratin-14 positive) cell types [see Additional
file 4, Figure S1]. In addition, cells were analyzed by
FACS for cell surface proteins which differentiate lumi-
nal versus basal/myoepithelial cells (EPCAM/CD49f)[25]
and cancer cells with tumor initiating capabilities
(CD44/CD24) [16]. These data demonstrated that cells
in the non-tumorigenic mammary epithelial cell line,
MCF-10A, formed a single broadly dispersed population,
which clustered by both CD44/CD24 and CD49f/
EPCAM staining (Figure 1A-B). In contrast, two distinct
populations were observed in hTERT-HMECs stained
with CD49f/EPCAM antibodies, which indicated the pre-
sence of both luminal and basal/myoepithelial cells [25].
To further assess the heterogeneity of the different cell
types, the percent coefficient of variance (% CV = SD/
mean * 100) was calculated from the histogram for each
stain. A heterogeneity factor was subsequently calculated
by multiplying the CV for each axis. The heterogeneity
factor for CD49f/EPCAM was larger for the hTERT-
HMEC compared to the MCF-10A cells, which suggests
HMEC cells are more heterogeneous in regard to lumi-
nal and myoepithelial cell populations. In addition,
CD24/CD44 staining of the established tumor cell lines
MCF-7 (Luminal ER+, PR+, HER2-), T47D (Luminal ER
+, PR+, HER2-) and MDA-MB-231 (Basal ER-, PR-,
HER2-) indicated these cells had one main population
(Figure 1A-B and Additional file 5, Figure S2). In con-
trast, PE1007070, PE1008032 and PE904557a (ER-, PR-,
HER2+) cells contained several populations, including a
CD44Hi/CD24Low population reported to have enhanced
tumor-initiating capacity [16]. Additionally, the hetero-
geneity factors for CD24/CD44 were higher for the
PE1007070, PE1008032 and PE904557a compared to the
MCF-7 and MDA-MB-231 cells. Together, these data
illustrate that the hTERT-HMEC and patient-derived PE
tumor samples are more heterogeneous compared to
established cell lines.
The process of establishing cell lines is likely to
impose selective pressure that favors highly proliferative
cell populations [8]. Therefore, we wanted to compare
the proliferation rates of cell lines and patient-derived
primary tumor cells. For this study, established cell lines
and patient-derived cells were treated with BrdU or
EdU, for either 30 minutes or 6 hours, and then ana-
lyzed by flow cytometry (Figure 1C). Established cell
lines were found to have BrdU/EdU incorporation ran-
ging from approximately 30% to 50% and 50% to 70%
when treated for 30 minutes and 60 minutes, respec-
tively. In contrast, patient-derived cells had significantly
lower BrdU/EdU incorporation, ranging between 0.4%
to 7%. Importantly, the proliferation rate observed in
patient-derived cells was similar to the 3.2% median
BrdU incorporation measured in tumors removed from
breast cancer patients treated with BrdU prior to sur-
gery [26]. These data demonstrate widely disparate pro-
liferation rates between established cancer cells lines
and patient tumors. Furthermore, short-term culture of
patient-derived tissue more closely matched the lower
proliferation rate observed in patients.
Since PE tumor cells were isolated from patients with
therapeutically recalcitrant disease, we wanted to deter-
mine if these samples were more resistant to che-
motherapies used in the treatment of metastatic breast
cancer [27]. To address this, we performed a four-day
dose response experiment comparing the efficacy of dif-
ferent drugs against established cell lines and patient-
derived cells (Figure 1D, Additional file 6, Table S4, and
Additional file 7, Figure S3). We observed that doxoru-
bicin, a chemotherapy that inhibits topoisomerase II [1],
reduced the viability of the established tumor cell lines
and patient-derived PE cells in a similar manner. In con-
trast, taxol, a microtubule inhibitor [28], and gemcita-
bine, a fluorinated pyrimidine [29], which both target
rapidly dividing cells, significantly reduced the viability
of established cell lines, but not the slowly dividing PE
cells. In general, these dose response experiments indi-
cated that patient-derived cells are more resistant to
anti-proliferative chemotherapy than established cell
lines, which correlates with the difference in mitotic
rates between these cells. Together these experiments
suggest that the patient-derived cells are resistant to sev-
eral chemotherapies used in the treatment of metastatic
breast cancer.
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Figure 1 Comparison of established cell lines and patient-derived cells. (A) MCF-10A, MCF-7, MDA-MB-231, T47D, hTERT-HMEC, PE1007070,
PE1008032 and PE904557a cells were stained with 7-AAD and a lineage cocktail in combination with CD44/CD24 or (B) CD49f/EPCAM and were
analyzed by FACS. The heterogeneity factor (HF) (to the right of each graph) was calculated by multiplying the percent CV of each axis.
(C) MCF-10A, MCF-7, MDA-MB-231, T47D, hTERT-HMEC, PE1007070, PE1008032 and PE904557a cells were treated with 10 μM BrdU or EdU for
either 30 minutes or six hours and then BrdU/EdU incorporation was analyzed by flow cytometry. The graph shows the percent BrdU/EdU
positive cells. (D) Dose response curves of doxorubicin, taxol and gemcitabine against MCF-7, MDA-MB-231, T47D, PE1007070, PE1008032 and
PE904557a cells after four days of treatment. Cell viability was measured using a luciferase-based ATP assay and was normalized to the vehicle
control. Error bars represent standard deviation. 7-AAD, 7-amino-actinomycin D; BrdU, 5-bromo-2-deoxyuridine; CV, coefficient of variance; EdU,
5-ethynyl-2’-deoxyuridine; FACS, fluorescence activated cell sorting; human mammary epithelial cells; hTERT, human telomerase; PE, pleural effusion.
Gligorich et al. Breast Cancer Research 2013, 15:R58
http://breast-cancer-research.com/content/15/4/R58
Page 7 of 15
Screen for compounds that selectively kill patient-derived
metastatic cancer cells
Due to their clinically important features, such as low
proliferation rates, chemoresistance and cellular hetero-
geneity, we reasoned that patient-derived tumor cells
would be well-suited to identify novel anti-cancer com-
pounds. Therefore, we performed a pilot screen utilizing
patient-derived tumor cells and hTERT-HMECs to iden-
tify compounds that selectively reduced the viability of
cancer cells without causing general cytotoxicity against
normal breast cells [see Additional file 1, Table S1]. A
560-compound library was generated at the University
of Utah Department of Chemistry that contains numer-
ous vetted natural product pharmacophores for anti-
cancer and antibiotic applications. The library was eval-
uated in duplicate at 20 μM against both hTERT-
HMECs and patient-derived PE1007070 cells. After four
days of treatment, a luciferase-based ATP assay was per-
formed to assess viability and the average value for each
compound was normalized to the DMSO vehicle con-
trol. For each compound, the percent viability of
PE1007070 cells was subtracted from the viability of
hTERT-HMECs to determine a compound’s percent
selectivity (Figure 2A). The average anti-cancer selectiv-
ity was calculated to be 10.2% and the hit limit was set
at 2.7 times the SD, which led to a hit rate of approxi-
mately 3% or 15 compounds. In addition, 20 μM doxor-
ubicin served as a positive control for each plate and
was used to calculate the Z’-factor [24]. The Z’-factor
for the DMSO and doxorubicin control was found to be
>0.5, which is considered an excellent assay [see Addi-
tional file 8, Figure S4].
We performed a follow-up dose response experiment
with hTERT-HMECs and PE1007070 cells to further
validate the selectivity of 14 hits identified in the screen
[see Additional file 9, Figure S5A and S5B]. About 50%
of the original hits exhibited selectivity for patient-
derived tumor cells compared to the hTERT-HMECs. In
order to provide additional validation of the drug screen,
we further evaluated hit 6, which was termed C-6
(Figure 2B), because it exhibited excellent selectivity for
tumor cells and can be readily synthesized utilizing a
unique palladium-catalyzed reductive coupling reaction
[22]. Thus, additional dose response experiments of C-6
were performed on PE cells representing the three
major subtypes of breast cancer including ER+/PR
+/HER2- (PE1008032), ER-/PR-/HER2- triple negative
(PE1007070), and ER-/PR-/HER+ (PE904557a) (Figure
2C). Whereas treatment with C-6 resulted in EC50
values in the range of 20 to 30 μM in both the ER+ and
triple negative PEs, the HER2+ tumor exhibited a higher
EC50 of 75.7 μM, which may suggest some resistance in
HER2+ tumors. Importantly, C-6 did not significantly
reduce the viability of the hTERT-HMECs. These results
demonstrated that C-6 has exceptional selectivity for
primary tumor cells compared to normal hTERT-
HMECs and provides additional validation of the
screening methodology.
After identifying the novel small molecule C-6, we
wanted to investigate the compound’s mechanism of
action. Since patient-derived tumor cells are a limited
resource, we needed to determine if established cell
lines could be employed for mechanism-of-action stu-
dies. A dose response experiment of C-6 was performed
on several established cell lines to determine the efficacy
of C-6 (Figure 2D). An EC50 of 11.0 μM was measured
for MCF-7 cells, 10.5 μM for MDA-MB-231cells and
8.29 μM for T47D cells, which suggests that C-6 has
slightly higher activity against the established cell lines
compared to the patient-derived cells. Importantly,
more than 70% of untransformed MCF-10A cells were
still viable even with 200 μM C-6 treatment which
further supports a cancer selective mechanism-of-action.
To begin to elucidate C-6’s cancer-selective mechan-
ism of action, we performed experiments to assess the
effects of this compound on proliferation and cell death.
Cell cycle analysis was performed using cell lines due to
the low baseline proliferation rate in PE cells. To study
C-6’s impact on the cell cycle, MCF-10A, MCF-7,
MDA-MB-231 and T47D cells were treated with DMSO
or 15 μM C-6 for 24 or 48 hours and were incubated
with BrdU for 30 minutes followed by FACS analysis
(Figure 2E). Interestingly, treatment with C-6 induced a
significant reduction in the percent of BrdU positive
cells (S phase) and increased the percentage of cells in
G1/G0 in each cancer cell line [see Additional file 10,
Figure S6]. In contrast, the untransformed MCF-10A
cells did not show a statistically significant difference in
their cell cycle profile. Together these data demonstrate
that C-6 causes a selective cytostatic phenotype in breast
cancer cell lines.
C-6 selectively induces a caspase-independent cell death
mechanism
Since C-6 was found to cause a reduction in prolifera-
tion, we wanted to determine if the compound was also
inducing cell death. Accordingly, hTERT-HMECs and
PE1007070 cells were cultured in monolayer and treated
with 20 μM C-6 and a live/dead assay was performed
(Figure 3A). The compound did not induce a gross
morphological phenotype in the hTERT-HMECs or a
significant increase in dead (ethidium bromide positive)
cells. In contrast, C-6 caused the PE1007070 cells to
become rounded up and led to an increase in the num-
ber of dead cells compared to the DMSO vehicle
control.
After determining that C-6 induced cell death in the
PE1007070 cells cultured in monolayer, we wanted to
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investigate if the small molecule was also active against
cells cultured in three-dimensions, which has been pro-
posed to be a better model of breast cancer due to
establishing cell-cell interactions similar to tumors in
vivo [30-32]. Accordingly, PE904557a, PE900642a and
PE1100025 cells were cultured overnight in ultra low
adhesion plates to facilitate aggregation. The resulting
aggregates were embedded in Matrigel and treated with
DMSO or either 30 or 60 μM C-6 for five days
(Figure 3B). The live/dead assay was performed and it
Figure 2 Identification of the small molecule C-6. (A) PE1007070 and hTERT-HMEC cells were treated with 20 μM of the compound library in
duplicate. After four days, a luciferase-based ATP assay was performed and data were normalized to DMSO vehicle control wells to determine
viability (%). The difference in viability between the hTERT-HMEC and PE1007070 cells is plotted. The hit limit was 2.7 times the standard
deviation. (B) The structure of C-6, which had a 62% difference in viability between the hTERT-HMEC and PE1007070 cells. (C) Dose response
curves of C-6 and EC50 values of hTERT-HMEC, PE1007070, PE1008032, and PE904557a cells and (D) MCF-10A, MCF-7, T47D and MDA-MB-231
cells after four days of treatment. N/A indicates data could not be fitted. (E) MCF-10A, MCF-7, MDA-MB-231 and T47D cells were treated with
DMSO or 15 μM C-6 for 24 or 48 hours followed by addition of 10 μM BrdU for 30 minutes. The cells were stained for BrdU and propidium
iodide and analyzed by flow cytometry. The average ± standard deviation of the percent BrdU positive cells (S phase) of three replicates was
calculated. Asterisks (*) denote P-value < 0.05. BrdU, 5-bromo-2-deoxyuridine; DMSO, dimethyl sulfoxide; HMEC, human mammary epithelial cells;
hTERT, human telomerase; PE pleural effusion.
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Figure 3 C-6 can induce death in cancer cells. (A) Differential interference contrast (DIC), calcein-AM fluorescence (green), and ethidium
homodimer-1 (red) images of hTERT-HMEC and PE1007070 cells cultured in two dimensions and treated with DMSO or 20 μM C-6 for five days
(Scale bar is 50 μm). (B) Confocal DIC, calcein-AM fluorescence (green), and ethidium homodimer-1 (red) images of PE904557a, PE900642a, and
PE1100025 cells cultured in three-dimensional Matrigel and treated with DMSO or either 30 or 60 μM C-6 for five days (Scale bar is 50 μm).
(C) MCF-10A, MCF-7, MDA-MB-231, PE1007070, PE1008032, PE904557a, and PE1100025 cells were treated with DMSO or 30 μM C-6 for 24 to
120 hours. The relative amount of released protease activity was measured using a luciferase-based AAF-Glo assay and these data were
normalized to total protein measured with a BCA assay. Asterisks (*) denote P-value < 0.05. DMSO, dimethyl sulfoxide; HMEC, human mammary
epithelial cells; hTERT, human telomerase; PE, pleural effusion.
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was found that C-6 was able to induce cell death in
patient-derived samples cultured in three-dimensions.
In order to quantify cell death more accurately, both
established cell lines and primary PE cells were treated
with DMSO or 30 μM C-6 and analyzed for proteases
released from dying cells every 24 hours for five days
using an AAF-Glo assay (Figure 3C). Treatment of
MCF-10A cells with C-6 did not cause an increase in
the relative AAF-Glo activity, which indicated that C-6
does not induce death in these cells. However, treatment
of MCF-7 cells and PE cells from three different patients
resulted in a significant increase in the relative AAF-Glo
activity compared to DMSO vehicle-treated cells. Inter-
estingly, MDA-MB-231 and PE1008032 cells, which
where both highly sensitive to C-6 in dose response
assays (Figure 2C and 2D), did not have increased AAF-
Glo activity, which suggests that C-6’s mechanism of
action in these cells is cytostatic. These data demon-
strate that C-6 can induce cell death and/or cytostatic
effects in tumor cells, but not in untransformed breast
cells.
We next wanted to investigate whether the death
mechanism was mediated through caspase-induced
apoptosis [33,34]. For this analysis, whole cell lysates
derived from either DMSO or C-6 treated cells were
analyzed by Western blot for cleaved caspase-3, caspase-
8, cleaved caspase-9, and PARP (Figure 4A). In contrast
to positive control compounds, C-6 did not induce clea-
vage of caspase-3, -8, -9, or PARP. A luminescence-
based caspase activity assay was also performed to
further confirm that C-6 was not activating caspase-3/7,
-8 or -9 (Figure 4B). Treatment with 30 μM C-6 for
Figure 4 C-6 does not induce caspase or PARP cleavage. (A) MCF-10A, MCF-7, T47D, MDA-MB-231, hTERT-HMEC, PE1007070, PE1008032 and
PE904557a cells were treated with DMSO (48 hours), 30 μM C-6 (48 hours), 1 μM staurosporine (24 hours) or 1 μg/mL TRAIL and 5 μM
doxorubicin (24 hours) and the resulting whole cell lysates were analyzed by Western blot for cleaved caspase 3, caspase 8, cleaved caspase 9
and PARP. (B) MCF-10A, MCF-7, T47D, MDA-MB-231, PE1007070, PE1008032, PE904557a and PE110025 cells were treated with DMSO (48 hours),
30 μM C-6 (24 and 48 hours) or 1 μM staurosporine (24 hours) and the relative amount of caspase activity was measured using a luciferase-
based Caspase-Glo assay and normalized to cell viability using a luciferase-based ATP assay. DMSO, dimethyl sulfoxide; HMEC, human mammary
epithelial cells; hTERT, human telomerase; PE, pleural effusion; TRAIL, tumor necrosis factor related apoptosis inducing ligand.
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24 or 48 hours did not induce significant caspase activ-
ity. In addition, the pan-caspase inhibitor Z-VAD-FMK
did not affect C-6 induced cell death in MCF-7 cells
(data not shown). Taken together, these data demon-
strate that C-6 can induce cell death through a caspase-
independent mechanism.
We next evaluated if C-6 induces cell death through
autophagy, which has been shown to occur in a caspase-
independent manner [35,36]. During autophagy, the pro-
tein LC3A/B-I is processed into the lower molecular
weight form LC3A/B-II [37], which can be detected by
Western blot. Cell lines and PE cells were treated with
DMSO, 30 μM C-6, 1 μM staurosporine or 50 μM
chloroquine, a compound known to cause LC3-II accu-
mulation [38]. The resulting whole cell lysates were ana-
lyzed by Western blot for the presence of LC3A/B-II
[see Additional file 11, Figure S7]. While chloroquine
led to a significant increase in LC3A/B-II levels in most
cells, C-6 only induced a small increase in LC3A/B-II
levels in the T47D cells, but not the other cell types
evaluated. In addition, autophagosomes were not
observed in MCF-7 cells by fluorescence microscopy
using LC3-EGFP (data not shown). Taken together,
these data demonstrate that C-6 induces caspase-inde-
pendent, non-autophagic cell death selectively in cancer
cells.
Discussion
The data presented here show that short-term culture
(<1 week) of non-passaged patient-derived tissue retains
many clinically-relevant characteristics of advanced stage
breast cancer, such as heterogeneous cell populations,
low cell proliferation and resistance to chemotherapy
(Figure 1) [11-13]. As such, the integration of patient-
derived tissue into drug development programs may
facilitate the identification of compounds that target
slowly dividing, metastatic tumor cells, which are intrin-
sically less sensitive to anti-proliferative chemotherapy.
Effectively incorporating patient-derived tissue into
drug screens is challenging due, in part, to constraints
on obtaining viable surgical specimens and difficulties
expanding primary cancer cells to quantities necessary
for large-scale screening. Recently, Gupta et al. devel-
oped a method that overcame some of these limitations.
They demonstrated that modified HMLER cells, which
were experimentally-derived by transforming normal
HMECs with hTERT, SV40 large-T antigen and hRas
(V12), could be readily cultured and screened to identify
anti-cancer compounds that selectively target cancer
stem cells [39]. Here, by performing a pilot screen of
560 compounds we demonstrate that patient-derived tis-
sue can be employed directly in drug discovery screen
without passaging. To our knowledge, our screen is the
first report to use non-passaged patient-derived breast
cancer cells in parallel with low passaged primary
immortalized HMECs to identify cancer selective small
molecules. Our pilot screen bypassed the necessity of
expansion in vitro by using viable cells collected from
patients with metastatic breast cancer who developed
pleural effusions [20]. As an example of the number of
cells that can be acquired during routine care of
patients, 1.0 × 109 viable cells were isolated from a sin-
gle patient (PE1007070), which is sufficient to culture
almost 700 96-well format plates at 15,000 cells/well
[see Additional file 2, Table S2]. If necessary, further
expansion of primary PE cells can be achieved in vivo. A
recent report by DeRose et al. demonstrated that tissue
derived from both solid tumors and pleural effusions
can be expanded by direct engraftment into immunode-
ficient mice [40]. Even after multiple serial transplanta-
tions, the grafts maintain the original tumor’s growth,
pathology and metastatic potential, which enables in
vivo expansion of patient-derived cells and reduces the
potential for culture-derived artifacts. While large scale
in vivo expansion of patient-derived tissue is labor-
intensive and costly, the identification of anti-cancer
compounds that target treatment-recalcitrant tumors
with low proliferation rates may lead to the identifica-
tion of novel targets and new treatments for patients
with metastatic or advanced disease.
As with any screening platform, reproducibility as well
as false positives and negatives are problems that can
reduce their usefulness in drug discovery [41]. In our
screen, we were able to achieve excellent Z’-factors,
which suggests limited plate-to-plate variability [see
Additional file 8, Figure S4] [24]. However, subsequent
dose response experiments of hits identified in the
screen suggested about a 40% to 50% false positive hit
rate [see Additional file 9, Figure S5]. It is likely that
this false positive rate is attributed to the poor solubility
of several compounds in the library, which contained
novel compounds that were not previously optimized
for biological assays. As an example, the calculated
cLogP values of the 14 compounds identified in the
initial screen ranged from 3.1 to 5.5 (average 4.2). Thus,
the use of small molecule libraries pre-selected for drug-
like compounds may reduce the false positive rate.
Our screen led to the identification of at least six
novel compounds that exhibited validated selectivity in a
secondary dose-response assay [see Additional file 8,
Figure S4]. Further studies were performed on hit C-6,
which was highly selective for cancer cells in the pri-
mary screen. The dose response experiments demon-
strated that C-6 had comparable activity and selectivity
for cancer cells representing the major subtypes of
breast cancer including ER+ (MCF-7, T47D and
PE1008032 cells), triple negative (MDA-MB-231 and
PE1007070 cells) and HER2+ (PE904557a cells)
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(Figure 2C and 2D). Cancer cells treated with C-6
exhibited varied effects, including cell death and reduced
proliferation, which were either not apparent or signifi-
cantly lower in normal breast cells. Importantly, we
found that C-6 does not cause apoptosis through the
caspase signaling cascade, which is a cell death pathway
often defective in chemoresistant cancer cells (Figure 4A
and 4B) [42-44].
While C-6 was highly selective in our in vitro assays,
its lipophilic properties, poor solubility and high cLogP
value (calculated 5.3) make in vivo evaluation challen-
ging. As such, assessment of the selectivity of C-6 for
cancer cells in mouse models, and evaluation of toxici-
ties, pharmacokinetics, and metabolic profiles will
require optimization of its structure to enhance its bioa-
vailabilty. Taken together, this study describes a small
molecule screen using primary metastatic tumor cells
and demonstrates the in vitro cancer selectivity of the
novel compound C-6.
Conclusions
Our results demonstrate that non-passaged primary
tumor cells are more heterogeneous, have reduced pro-
liferation rates and exhibit resistance to chemotherapy
compared to established cell lines. Since patient-derived
cells optimally replicate tumor growth, survival and che-
moresistance mechanisms acquired in patients during
disease progression, their use in drug discovery may
lead to novel cancer therapeutics that target advanced
stages of breast cancer. One of the compounds identi-
fied in the screen, C-6, was found to selectively inhibit
cell proliferation and induce cell death in several
patient-derived tumor cells via a caspase-independent
mechanism. Our data suggest that patient-derived cells
are a valuable tool with high potential in the develop-
ment of new cancer drugs.
Additional material
Additional file 1: Supplemental table 1. Description of the screen,
protocol, and data analysis.
Additional file 2: Supplemental table 2. Primary cells patient
background and chemotherapy history.
Additional file 3: Supplemental table 3. Tumorigenicity of
immortalized hTERT-HMEC cells in NOD/SCID mice.
Additional file 4: Supplemental figure 1. Patient-derived cells retain
mammary epithelial cell lineage markers during in vitro culture.
PE1007070, PE1008032, and PE904557a cells were stained for mammary
epithelial cell markers cytokeratin 8 (K8) and cytokeratin 14 (K14) before
in vitro culture and after 96 hours of in vitro culture. Nuclei are stained
with DAPI. Scale bar is 10 μm.
Additional file 5: Supplemental figure 2. Characterization of cells by
flow cytometry. (A) hTERT-HMEC, (B) PE1008032 (C) PE1007070 and (D)
PE904557a were analyzed by flow cytometry for FSC/SSC, 7-AAD and
Lineage markers.
Additional file 6: Supplemental table 4. EC50 values of chemotherapies
after four days of treatment.
Additional file 7: Supplemental figure 3. Chemosensitivity of
established cell lines and patient-derived cells. Dose response curves of
bortezomib, LBH589, cisplatin and 17-AAG against MCF-7, MDA-MB-231,
T47D, PE1007070, PE1008032 and PE904557a cells after four days of
treatment. Cell viability was determined using a luciferase-based ATP
viability assay, which was normalized to the untreated vehicle control.
Error bars represent the standard deviation of four replicates.
Additional file 8: Supplemental figure 4. The Z’-Factor for each plate
was calculated using the average percent viability of the 20 μM
doxorubicin wells (positive control) and 0.2% v/v DMSO wells (negative
control).
Additional file 9: Supplemental figure 5. (A) Dose response of the top
14 selective hits from the screen against the hTERT-HMEC and
PE1007070 cells after four days of treatment. Cell viability was
determined using a luciferase-based ATP viability assay, which was
normalized to the untreated vehicle control. Error bars represent
standard deviation. N/A denotes that data could not be fitted. (B)
Representative small molecules and substructures of hits identified from
the screen.
Additional file 10: Supplemental figure 6. MCF-10A, MCF-7, T47D, and
MDA-MB-231 cells were treated with DMSO or 15 μM C-6 for 24 hours or
48 hours followed by addition of 10 μM BrdU for 30 minutes. The cells
were stained for BrdU, PI and analyzed by FACS to determine the
percentage of cells in the G1/G0, S, and G2/M phase. Asterisks (*) denote
P-value < 0.05 of difference between percentages of cells in S phase.
Additional file 11: Supplemental figure 7. C-6-induced cell death is
independent of autophagy. MCF-10A, MCF-7, MDA-MB-231, T47D, hTERT-
HMEC, PE1007070, PE108032 and PE904557a cells were treated with
DMSO (48 hours), 30 μM C-6 (48 hours), 1 μM staurosporine (24 hours) or
50 μM chloroquine (24 hours) and resulting whole cell lysates were
analyzed by Western blot for LC3A/B.
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